NCT01195805已完成不适用
The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.
Regional Hospital Holstebro1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Bloodpressure
研究概览
简要总结
The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.
详细描述
Purpose of the study is to examine the effect of amiloride and spironolactone on
- Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
- Pulsewave velocity, augmentation index central bloodpressure,
- Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
- Ambulatory bloodpressure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hypertension,
- •BMI 18,5-30,
- •non-smoker
排除标准
- •Not using contraceptives
- •Other illnesses
- •Drug or alcohol abuse
研究组 & 干预措施
Amiloride
Active Comparator
干预措施: Amiloride (Drug)
Spironolactone
Active Comparator
干预措施: Spironolactone (Drug)
Placebo
Placebo Comparator
1 tablet twice a day for 28 days
干预措施: Placebo (Other)
结局指标
主要结局
Bloodpressure
时间窗: 24-hours and examination
次要结局
未报告次要终点
研究者
Erling Bjerregaard Pedersen
professor
Regional Hospital Holstebro
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Effect of Amiloride and Spironolactone in Patients With HypertensionHypertensionNCT01388088Erling Bjerregaard Pedersen23
已完成
1 期
The Effect of Amiloride and Spironolactone in Healthy PersonsHigh Blood PressureNCT00857909Regional Hospital Holstebro30
进行中（未招募）
1 期
The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in patients with hypertension - HASSMedDRA version: 12.1Level: LLTClassification code 10004254Term: Benign essential hypertensionHypertensionEUCTR2010-020599-47-DKDepartments of Medical Research and Medicine25
进行中（未招募）
不适用
The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in healthy patientsHypertensionEUCTR2008-003336-38-DKDepartment of Medical Research25
Unknown
不适用
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney DiseaseDiabetic NephropathiesHypertensionNCT01918488University of Southern Denmark80